Evidence map›Paper›PMID 35451745›Full record

ArticleProbiotics and antimicrobial proteins2022

Susceptibility of Candida albicans Strains Isolated from Vaginal Secretion in Front of the Mycocins of Wickerhamomyces anomalus.

Lana Rubia B Rosseto, Eloiza Cristina Martelli, Jessica Cassia da Silva, Bruna Larissa Nascimento, Daniele S B Junges, Mateus F Delabeneta, Ana Paula Paris, Marcos Ereno Auler, Rafael Andrade Menolli, Rita C G Simão and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. The KillerMicroorganisms · 2024
    Review
  2. Probiotic Yeasts: A Developing Reality?Journal of fungi (Basel, Switzerland) · 2024
    Review
  3. Article
  4. The effects ofClinical pathology (Thousand Oaks, Ventura County, Calif.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Lana Rubia B RossetoHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Eloiza Cristina MartelliHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Jessica Cassia da SilvaHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Bruna Larissa NascimentoHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Daniele S B JungesHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Mateus F DelabenetaHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Ana Paula ParisHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Marcos Ereno AulerUniversidade Estadual Do Centro Oeste Unicentro, Guarapuava, PR, Brazil.
Rafael Andrade MenolliHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Rita C G SimãoHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil.
Claudete R PaulaFaculdade de Odontologia, Universidade de São Paulo USP, São Paulo, SP, Brazil.
Rinaldo F GandraHospital Universitário Do Oeste Do Paraná, Universidade Estadual Do Oeste Do Paraná Unioeste, Cascavel, PR, Brazil. rinaldo.gandra@unioeste.br.
Universidade Estadual do Oeste do Paraná · BRUniversidade de São Paulo · BRUniversidade Estadual do Centro-Oeste · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycocins are substances that have the potential to affect other sensitive yeasts or microorganisms. Wickerhamomyces anomalus is a yeast that produces mycocins that have great biotechnological potential, being highly competitive in many habitats, as it is adaptable to a wide range of environmental conditions. Thus, they are targets for studies in different areas, including the environment, industry, and medical sciences. Yeasts of the genus Candida are of great importance due to the high frequency with which they colonize and infect the human host. Yeast infections are often difficult to treat due to the acquisition of resistance against antifungals, leading to studies focusing in new treatment alternatives. This work aims to verify the inhibition of Candida albicans isolated from vaginal secretion by mycocins produced by Wickerhamomyces anomalus. Tests were carried out in solid medium and microdilution tests, where mycocins proved to be efficient in inhibiting the growth of C. albicans, hemolysis, and irritation in an organotypic model, which showed that the mycocins produced by W. anomalus are safe and non-irritating. Thus, the results of this work can provide scientific evidence for the application of mycocins in the production of new antifungal alternatives.

Indexed as

Candida albicansSaccharomycetalesAntifungal AgentsCandidaFemaleHumansYeastsAntifungal AgentsAntifungalKiller toxinsVulvovaginitis

Identifiers

PMID35451745
OpenAlexW4224273685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.